Research graph
References from Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?. Local targets link to admitted publications; unresolved targets remain external evidence.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms
10.1038/s41375-022-01620-2 · 2022 · External reference
Diffuse large B-cell lymphoma
10.1056/nejmra2027612 · 2021 · External reference
10.3390/diagnostics14111167
10.3390/diagnostics14111167 · External reference
Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis
10.1177/03936155221149749 · 2023 · External reference
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
10.1182/blood-2017-07-740993 · 2018 · External reference
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
10.1182/blood-2015-12-686550 · 2016 · External reference
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
10.1038/nature18294 · 2016 · External reference
Molecular profiling of EBV-associated diffuse large B-cell lymphoma
10.1038/s41375-022-01804-w · 2023 · External reference
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype
10.1182/blood-2018-10-879015 · 2019 · External reference
PD-L1-expressing macrophages infiltrate diffuse large B-cell lymphoma and promote lymphoma growth in a MYC-driven experimental model
10.1038/s41408-025-01281-1 · 2025 · External reference
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma
10.1200/jco.19.01389 · 2019 · External reference
10.3389/fimmu.2025.1647045
10.3389/fimmu.2025.1647045 · External reference
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
10.1182/blood-2015-02-629600 · 2015 · External reference
Comprehensive analysis of tumor microenvironment and PD-L1 expression associations with clinicopathological features and prognosis in diffuse large B-cell lymphoma
2025 · External reference
Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma
10.1002/cam4.2316 · 2019 · External reference
10.3390/medicina62061117
10.3390/medicina62061117 · External reference
10.1056/nejm199309303291402
10.1056/nejm199309303291402 · External reference
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
10.1182/blood-2003-05-1545 · 2004 · External reference
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
10.1200/jco.2011.41.0985 · 2012 · External reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification
10.1200/jco.2013.54.8800 · 2014 · External reference
PD-L1 and tumor-associated macrophages in de novo DLBCL
10.1182/bloodadvances.2018020602 · 2019 · External reference
PD-L1 immunohistochemistry comparability study in real-life clinical samples: Results of Blueprint phase 2 project
10.1016/j.jtho.2018.05.013 · 2018 · External reference
10.1186/s12885-019-5466-y
10.1186/s12885-019-5466-y · External reference
10.1186/s12885-020-6550-z
10.1186/s12885-020-6550-z · External reference
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: Results from a French multicenter clinical trial
10.1038/leu.2014.137 · 2014 · External reference
Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer
10.5858/arpa.2018-0043-oa · 2019 · External reference
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
10.1158/1078-0432.ccr-13-0855 · 2013 · External reference
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
10.1182/blood-2013-10-535443 · 2014 · External reference
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
10.1038/s41408-019-0233-5 · 2019 · External reference
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain
10.1097/pas.0000000000000297 · 2014 · External reference
Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma
10.1002/cam4.2316 · ExternalCitation · doi-reference
PD-L1 immunohistochemistry comparability study in real-life clinical samples: Results of Blueprint phase 2 project
10.1016/j.jtho.2018.05.013 · ExternalCitation · doi-reference
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: Results from a French multicenter clinical trial
10.1038/leu.2014.137 · ExternalCitation · doi-reference
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
10.1038/nature18294 · ExternalCitation · doi-reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms
10.1038/s41375-022-01620-2 · ExternalCitation · doi-reference
Molecular profiling of EBV-associated diffuse large B-cell lymphoma
10.1038/s41375-022-01804-w · ExternalCitation · doi-reference
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
10.1038/s41408-019-0233-5 · ExternalCitation · doi-reference
PD-L1-expressing macrophages infiltrate diffuse large B-cell lymphoma and promote lymphoma growth in a MYC-driven experimental model
10.1038/s41408-025-01281-1 · ExternalCitation · doi-reference
10.1056/nejm199309303291402
10.1056/nejm199309303291402 · ExternalCitation · doi-reference
Diffuse large B-cell lymphoma
10.1056/nejmra2027612 · ExternalCitation · doi-reference
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain
10.1097/pas.0000000000000297 · ExternalCitation · doi-reference
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
10.1158/1078-0432.ccr-13-0855 · ExternalCitation · doi-reference
Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis
10.1177/03936155221149749 · ExternalCitation · doi-reference
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
10.1182/blood-2003-05-1545 · ExternalCitation · doi-reference
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
10.1182/blood-2013-10-535443 · ExternalCitation · doi-reference
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
10.1182/blood-2015-02-629600 · ExternalCitation · doi-reference
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
10.1182/blood-2015-12-686550 · ExternalCitation · doi-reference
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
10.1182/blood-2017-07-740993 · ExternalCitation · doi-reference
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype
10.1182/blood-2018-10-879015 · ExternalCitation · doi-reference
PD-L1 and tumor-associated macrophages in de novo DLBCL
10.1182/bloodadvances.2018020602 · ExternalCitation · doi-reference
10.1186/s12885-019-5466-y
10.1186/s12885-019-5466-y · ExternalCitation · doi-reference
10.1186/s12885-020-6550-z
10.1186/s12885-020-6550-z · ExternalCitation · doi-reference
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma
10.1200/jco.19.01389 · ExternalCitation · doi-reference
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
10.1200/jco.2011.41.0985 · ExternalCitation · doi-reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification
10.1200/jco.2013.54.8800 · ExternalCitation · doi-reference
10.3389/fimmu.2025.1647045
10.3389/fimmu.2025.1647045 · ExternalCitation · doi-reference
10.3390/diagnostics14111167
10.3390/diagnostics14111167 · ExternalCitation · doi-reference
10.3390/medicina62061117
10.3390/medicina62061117 · ExternalCitation · doi-reference
Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer
10.5858/arpa.2018-0043-oa · ExternalCitation · doi-reference
